213 related articles for article (PubMed ID: 28054503)
1. Inhibition of telomerase using BIBR1532 enhances doxorubicin-induced apoptosis in pre-B acute lymphoblastic leukemia cells.
Bashash D; Zareii M; Safaroghli-Azar A; Omrani MD; Ghaffari SH
Hematology; 2017 Jul; 22(6):330-340. PubMed ID: 28054503
[TBL] [Abstract][Full Text] [Related]
2. Telomerase inhibition by non-nucleosidic compound BIBR1532 causes rapid cell death in pre-B acute lymphoblastic leukemia cells.
Bashash D; Ghaffari SH; Mirzaee R; Alimoghaddam K; Ghavamzadeh A
Leuk Lymphoma; 2013 Mar; 54(3):561-8. PubMed ID: 22957790
[TBL] [Abstract][Full Text] [Related]
3. Contributory role of microRNAs in anti-cancer effects of small molecule inhibitor of telomerase (BIBR1532) on acute promyelocytic leukemia cell line.
Pourbagheri-Sigaroodi A; Bashash D; Safaroghli-Azar A; Farshi-Paraasghari M; Momeny M; Mansoor FN; Ghaffari SH
Eur J Pharmacol; 2019 Mar; 846():49-62. PubMed ID: 30658112
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of tachykinin NK
Bayati S; Bashash D; Ahmadian S; Safaroghli-Azar A; Alimoghaddam K; Ghavamzadeh A; Ghaffari SH
Eur J Pharmacol; 2016 Nov; 791():274-283. PubMed ID: 27609608
[TBL] [Abstract][Full Text] [Related]
5. A combination of the telomerase inhibitor, BIBR1532, and paclitaxel synergistically inhibit cell proliferation in breast cancer cell lines.
Shi Y; Sun L; Chen G; Zheng D; Li L; Wei W
Target Oncol; 2015 Dec; 10(4):565-73. PubMed ID: 25916999
[TBL] [Abstract][Full Text] [Related]
6. The telomerase inhibitor MST-312 synergistically enhances the apoptotic effect of doxorubicin in pre-B acute lymphoblastic leukemia cells.
Ghasemimehr N; Farsinejad A; Mirzaee Khalilabadi R; Yazdani Z; Fatemi A
Biomed Pharmacother; 2018 Oct; 106():1742-1750. PubMed ID: 30170357
[TBL] [Abstract][Full Text] [Related]
7. Suppression of c-Myc using 10058-F4 exerts caspase-3-dependent apoptosis and intensifies the antileukemic effect of vincristine in pre-B acute lymphoblastic leukemia cells.
Sheikh-Zeineddini N; Bashash D; Safaroghli-Azar A; Riyahi N; Shabestari RM; Janzamin E; Safa M
J Cell Biochem; 2019 Aug; 120(8):14004-14016. PubMed ID: 30957273
[TBL] [Abstract][Full Text] [Related]
8. BIBR1532, a Selective Telomerase Inhibitor, Enhances Radiosensitivity of Non-Small Cell Lung Cancer Through Increasing Telomere Dysfunction and ATM/CHK1 Inhibition.
Ding X; Cheng J; Pang Q; Wei X; Zhang X; Wang P; Yuan Z; Qian D
Int J Radiat Oncol Biol Phys; 2019 Nov; 105(4):861-874. PubMed ID: 31419512
[TBL] [Abstract][Full Text] [Related]
9. Direct short-term cytotoxic effects of BIBR 1532 on acute promyelocytic leukemia cells through induction of p21 coupled with downregulation of c-Myc and hTERT transcription.
Bashash D; Ghaffari SH; Zaker F; Hezave K; Kazerani M; Ghavamzadeh A; Alimoghaddam K; Mosavi SA; Gharehbaghian A; Vossough P
Cancer Invest; 2012 Jan; 30(1):57-64. PubMed ID: 22236190
[TBL] [Abstract][Full Text] [Related]
10. BIBR 1532 increases arsenic trioxide-mediated apoptosis in acute promyelocytic leukemia cells: therapeutic potential for APL.
Bashash D; Ghaffari SH; Zaker F; Kazerani M; Hezave K; Hassani S; Rostami M; Alimoghaddam K; Ghavamzadeh A
Anticancer Agents Med Chem; 2013 Sep; 13(7):1115-25. PubMed ID: 23293885
[TBL] [Abstract][Full Text] [Related]
11. Targeting telomerase activity by BIBR1532 as a therapeutic approach in germ cell tumors.
Mueller S; Hartmann U; Mayer F; Balabanov S; Hartmann JT; Brummendorf TH; Bokemeyer C
Invest New Drugs; 2007 Dec; 25(6):519-24. PubMed ID: 17534576
[TBL] [Abstract][Full Text] [Related]
12. Selective cytotoxicity and telomere damage in leukemia cells using the telomerase inhibitor BIBR1532.
El-Daly H; Kull M; Zimmermann S; Pantic M; Waller CF; Martens UM
Blood; 2005 Feb; 105(4):1742-9. PubMed ID: 15507522
[TBL] [Abstract][Full Text] [Related]
13. [The influence of compound aITEL1296 on telomerase activity and the growth of cancer cells].
Kovalenko NA; Zhdanov DD; Bibikova MV; Gotovtseva VIu
Biomed Khim; 2011; 57(5):501-10. PubMed ID: 22629600
[TBL] [Abstract][Full Text] [Related]
14. Effects of telomerase inhibitor on epigenetic chromatin modification enzymes in malignancies.
Biray Avci C; Dogan F; Ozates Ay NP; Goker Bagca B; Abbaszadeh Z; Gunduz C
J Cell Biochem; 2018 Dec; 119(12):9817-9824. PubMed ID: 30145821
[TBL] [Abstract][Full Text] [Related]
15. Arsenic trioxide and BIBR1532 synergistically inhibit breast cancer cell proliferation through attenuation of NF-κB signaling pathway.
Nasrollahzadeh A; Bashash D; Kabuli M; Zandi Z; Kashani B; Zaghal A; Mousavi SA; Ghaffari SH
Life Sci; 2020 Sep; 257():118060. PubMed ID: 32645343
[TBL] [Abstract][Full Text] [Related]
16. Kras mutations increase telomerase activity and targeting telomerase is a promising therapeutic strategy for Kras-mutant NSCLC.
Liu W; Yin Y; Wang J; Shi B; Zhang L; Qian D; Li C; Zhang H; Wang S; Zhu J; Gao L; Zhang Q; Jia B; Hao L; Wang C; Zhang B
Oncotarget; 2017 Jan; 8(1):179-190. PubMed ID: 27329725
[TBL] [Abstract][Full Text] [Related]
17. Enhancement of adriamycin cytotoxicity by sodium butyrate involves hTERT downmodulation-mediated apoptosis in human uterine cancer cells.
Yu M; Kong H; Zhao Y; Sun X; Zheng Z; Yang C; Zhu Y
Mol Carcinog; 2014 Jul; 53(7):505-13. PubMed ID: 23359532
[TBL] [Abstract][Full Text] [Related]
18. PI3K-δ inhibition using CAL-101 exerts apoptotic effects and increases doxorubicin-induced cell death in pre-B-acute lymphoblastic leukemia cells.
Safaroghli-Azar A; Bashash D; Sadreazami P; Momeny M; Ghaffari SH
Anticancer Drugs; 2017 Apr; 28(4):436-445. PubMed ID: 28125433
[TBL] [Abstract][Full Text] [Related]
19. RITA enhances chemosensivity of pre-B ALL cells to doxorubicin by inducing p53-dependent apoptosis.
Kazemi A; Safa M; Shahbazi A
Hematology; 2011 Jul; 16(4):225-31. PubMed ID: 21756539
[TBL] [Abstract][Full Text] [Related]
20. Role of p53 transcription factor in determining the efficacy of telomerase inhibitors in cancer treatment.
Gala K; Jain M; Shah P; Pandey A; Garg M; Khattar E
Life Sci; 2024 Feb; 339():122416. PubMed ID: 38216120
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
